Browse the evidence

GLP-1 receptor agonists provide cardiovascular protection by reducing major adverse cardiac events (MACE), independent of substantial glucose lowering, through mechanisms including improved endothelial function and reduced inflammation.

GLP-1 medications offer significant cardiovascular protection, reducing the risk of heart attack, stroke, and cardiovascular death. This benefit exists even in non-diabetic obese patients, likely due to improved blood vessel function and reduced inflammation, not just weight loss or blood sugar control.

SGLT-2 inhibitors and GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE) and end-stage kidney disease (ESKD) in Type 2 Diabetes patients, with SGLT-2i showing specific superiority for kidney outcomes.

For Type 2 Diabetes patients with heart or kidney risks, prioritize SGLT-2 inhibitors or GLP-1 RAs. These drugs do more than lower blood sugar; they significantly reduce the risk of heart attacks, heart failure hospitalizations, and kidney failure. SGLT-2 inhibitors are particularly strong for protecting the kidneys.

Semaglutide improves cardiovascular outcomes, including reducing the risk of major adverse cardiovascular events (MACE), in patients with type 2 diabetes.

If you have type 2 diabetes and heart disease, kidney disease, or heart failure, ask your doctor about adding a GLP-1 RA like semaglutide. It can significantly lower your risk of heart attack, stroke, and heart failure, even if your blood sugar is already well-controlled.

Genetically modeled GLP-1 and GIP receptor agonism reduces fatty food liking and increases vegetarian food liking.

Genetic evidence suggests that activating GLP-1 and GIP receptors shifts food preferences away from fatty foods and towards vegetarian options. This change in food preference may contribute to the observed reduction in binge drinking.

Tirzepatide treatment (10 mg or 15 mg once weekly for 72 weeks) significantly improves self-reported health-related quality of life (HRQoL) in adults with obesity or overweight and type 2 diabetes, specifically in physical functioning, bodily pain, general health, vitality, and social functioning.

If you have type 2 diabetes and are overweight or obese, treatment with tirzepatide (Mounjaro/Zepbound) can significantly improve your daily quality of life. This includes feeling less pain, having more energy, and being more socially active. The improvements are seen in both physical and mental well-being, and they are greater for those who lose more weight. Talk to your doctor about whether this once-weekly injection is right for you, especially if you are struggling with physical limitations due to your weight.

Glucagon regulates glucose and amino acid homeostasis and counters hypoglycemia.

Glucagon is a natural hormone that helps keep your blood sugar and amino acid levels stable. It acts as a counter-regulatory mechanism to prevent hypoglycemia, making it essential for metabolic balance.

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk.

If you have Type 2 Diabetes and are at high risk for heart problems, ask your doctor about GLP-1 RAs like liraglutide or semaglutide. These drugs not only help control blood sugar but have been proven in major studies to significantly lower your risk of heart attack, stroke, and cardiovascular death. The benefits extend beyond glucose control to direct heart protection.

Obesity is a chronic disease driven by dysfunctional adipose tissue and dysregulated energy homeostasis, requiring medical treatment rather than solely lifestyle changes.

Obesity is a medical condition, not a moral failing. If you have obesity, you need medical treatment, not just willpower. Seek a doctor who understands this and offers evidence-based therapies.

Naltrexone/bupropion combination therapy produces moderate weight loss (up to 6.1% vs placebo) and improves metabolic markers, but carries risks of seizures and psychiatric side effects.

This medication can help you lose weight by affecting brain chemicals that control hunger. It is taken twice daily and must be started at a low dose to avoid side effects like nausea, constipation, or headaches. It is not suitable for people with a history of seizures, eating disorders, or heart problems. You must stop the medication if you do not lose at least 5% of your body weight after 12 weeks.

Metformin is the first-line pharmacological treatment for T2DM and prediabetes, offering significant reduction in microvascular complications and diabetes-related deaths through mechanisms including inhibition of hepatic gluconeogenesis and increased insulin sensitivity.

Metformin is the standard first-line drug for T2DM and prediabetes. It reduces complications and deaths. If you experience stomach upset, ask your doctor about slow-release versions or slow titration to manage side effects.

SGLT2 receptor inhibitors (SGLT2R-i) provide significant cardiovascular and renal benefits, including reduced cardiovascular mortality and heart failure hospitalization, in addition to glycaemic control, by preventing glucose reabsorption in the kidneys.

SGLT2 inhibitors (like empagliflozin or dapagliflozin) are powerful drugs for T2DM patients with heart or kidney risks. They significantly reduce heart failure hospitalizations and mortality. Maintain good hygiene to minimize the risk of genital infections.

Obesity acts as an independent risk factor and driver for cardiovascular diseases through mechanisms including insulin resistance, endothelial dysfunction, systemic inflammation, and neurohormonal activation, leading to hypertension, heart failure, coronary artery disease, and stroke.

High body weight is a major biological driver of heart disease, not just a cosmetic issue. Addressing it requires medical and public health strategies, not just willpower, because it triggers harmful biological changes like inflammation and high blood pressure.

GLP-1 receptor agonists (e.g., semaglutide) and dual agonists (e.g., tirzepatide) are effective pharmacotherapies for obesity, achieving 10-20% mean body weight reduction, but their use is limited by stigma, regulatory barriers, and lack of insurance coverage.

If you have obesity, ask your doctor about GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide). These are proven to help with significant weight loss. If insurance doesn't cover them, advocate for policy changes or look for patient assistance programs.

GLP-1 receptor agonists (GLP-1RAs) induce weight loss primarily through central nervous system (CNS) mechanisms, specifically by acting on GLP-1 receptors in the dorsal vagal complex (NTS and area postrema) and hypothalamic nuclei, rather than through peripheral signaling alone.

GLP-1 medications like semaglutide work by signaling to your brain to reduce hunger and food intake, not just by slowing digestion. Understanding this brain-gut connection helps explain why these drugs are effective for weight loss and why side effects like nausea occur via specific brain pathways.

For patients with Class II obesity (BMI 35-39.9 kg/m2), tirzepatide is significantly superior to other medications and endoscopic procedures, but its weight loss efficacy is inferior to major surgeries like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB).

If you have Class II obesity (BMI 35-39.9), surgery (like gastric bypass) will likely help you lose more weight than medication. However, if you are not ready for or cannot undergo surgery, newer medications like tirzepatide are still significantly more effective than other non-surgical options, though they will not achieve the same level of weight loss as surgery.

Once-weekly subcutaneous semaglutide at 2.4 mg significantly improves heart failure symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, independent of weight loss mechanisms.

For patients with HFpEF and obesity, once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, exercise capacity, and quality of life. This treatment addresses a major unmet need in this population, offering benefits beyond weight loss alone. Patients should discuss this option with their healthcare provider, considering the potential for gastrointestinal side effects and the significant clinical improvements observed.

GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in T2D patients, whereas sulphonyureas are associated with increased cardiovascular mortality.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about GLP-1RA or SGLT2i medications, as they protect your heart and kidneys. Avoid sulphonyureas if possible, as they may increase cardiovascular risk.

Excess body fat during childhood and adolescence causally increases the risk of developing Polycystic Ovary Syndrome (PCOS) in adulthood, independent of adult body size.

Maintaining healthy body composition during childhood and adolescence is critical for preventing PCOS later in life. Even if adult weight is normal, excess fat during youth leaves a lasting metabolic imprint (insulin resistance/low SHBG) that increases PCOS risk. Early lifestyle interventions are the most effective prevention strategy.

Lifestyle interventions for obesity typically result in modest long-term weight loss (5-10%) and high rates of weight regain due to potent biological adaptations, specifically increased appetite and reduced energy expenditure.

If you lose weight through diet and exercise, expect your body to fight back with increased hunger and a slower metabolism. This is a normal biological response, not a failure of willpower. To maintain loss, you may need ongoing support or pharmacological intervention to counteract these specific hormonal signals.

Obesity significantly increases the risk of cardiovascular diseases (CVDs), including hypertension, coronary artery disease, heart failure, and arrhythmias, through mechanisms involving inflammation, endothelial dysfunction, and cardiac structural changes.

If you have obesity, you are at a significantly higher risk for heart disease, high blood pressure, and heart failure. This risk is driven by inflammation and structural changes in the heart. Weight loss through lifestyle changes is crucial for managing these risks. Regular screening for blood pressure, cholesterol, and heart function is recommended.

Obesity is a major risk factor for various cancers, including endometrial, ovarian, prostate, colorectal, pancreatic, liver, gallbladder, kidney, thyroid, and meningioma, as well as hematological malignancies like multiple myeloma and leukemia.

Maintaining a healthy weight reduces your risk of developing several types of cancer, including colorectal, kidney, and endometrial cancer. Weight management through lifestyle changes is a key preventive strategy.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide reduce body weight primarily by suppressing energy intake through activation of GLP-1 receptors in the central nervous system (CNS) and peripheral vagal afferent pathways, rather than by increasing energy expenditure.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, primarily by reducing appetite and food intake through brain and gut signaling. They are taken once weekly. While they achieve significant weight loss (15-20%+ in trials), real-world results vary, and about a third of users may not lose enough weight to be clinically effective. Common side effects like nausea are frequent but often manageable with dose titration. These drugs are not a magic bullet for everyone, especially those with type 2 diabetes or lower starting weights, and require medical supervision.

Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.

Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, tirzepatide (up to 15 mg weekly) can help reduce your risk of heart failure worsening and cardiovascular death. It is taken as a weekly injection, escalated to the maximum tolerated dose.